Axxam is an innovative Partner Research Organization (iPRO). We are a leading provider of integrated discovery services across Life Sciences industries including: pharmaceuticals, crop protection, animal health, cosmetics, fragrances, food and beverages. We have consolidated expertise across a broad range of discovery disciplines and innovative technologies including: assay development, high-throughput screening of both the Axxam high quality compound collections (synthetic and natural)  or those provided by our clients, compound management, hit identification and hit validation. Our performance-driven approach has been recognized by our clients as key to the success for their discovery programs. Axxam is also engaged in alliance-based research towards innovative small molecule therapies for diseases with a high unmet medical need. Axxam’s business terms are flexible, ranging from fee-for-service to risk-sharing deal structures.

Discovery Services

Cell-based Assay

Development

Biochemical Assay

Development

High-Throughput

Screening

Hit Follow-up and

Electrophysiology

Compound Collections

Ready-to-go Assays

Live the i-PRO experience

Axxam SpA expands to Denmark; opens office in Copenhagen

Axxam SpA expands to Denmark; opens office in Copenhagen Sep 27, 2018 Axxam SpA (Milan/Italy), a privately-owned innovative Partner Research Organization (iPRO) with a strong and leading expertise for the identification and characterization of bioactive compounds,...

Axxam SpA is a member of an international consortium for the further development of a promising drug against neuropathic pain

Axxam SpA is a member of an international consortium for the further development of a promising drug against neuropathic pain Milan (Italy), 20 September 2018 Axxam is proud to announce its participation to a consortium of international partners, held by the Danish...

Axxam SpA is a member of the RESOLUTE consortium

Axxam SpA is a member of the RESOLUTE consortium Milan, 4th July 2018. Axxam is proud to announce its participation to the RESOLUTE (Research empowerment on solute carriers) consortium, a public-private research partnership supported by the Innovative Medicines...

Acousia Therapeutics Announces €10 Million Series B Financing to Advance its Hearing Loss Portfolio

Acousia Therapeutics Announces €10 Million Series B Financing to Advance its Hearing Loss Portfolio May 14th, 2018 - Milan (Italy) - Axxam is proud to announce that Acousia Therapeutics (Tubingen; Germany), a biotech company participated by Axxam and focused to...

Axxam S.p.A. collaborates with GenSight Biologics S.A. to support Clinical Trials of an optogenetic-based gene therapy drug for sight-threatening diseases

Axxam S.p.A. collaborates with GenSight Biologics S.A. to support Clinical Trials of an optogenetic-based gene therapy drug for sight-threatening diseases April 24th 2018 - Milan (Italy) - Axxam S.p.A. announced today a collaboration with GenSight Biologics S.A. in...

AXXAM expands its natural products service business

AXXAM expands its natural products service business Thursday 22nd March 2018, Milan - Axxam SpA (“AXXAM”) announces today the acquisition of all shares of IMAX Discovery GmbH (“IMAX Discovery”) held by IMD Natural Solutions GmbH (“INS”) to make IMAX Discovery a...

Axxam and Proximagen enter into a strategic collaboration for the discovery of novel molecules against targets for CNS disorders, pain and inflammation

Axxam and Proximagen enter into a strategic collaboration for the discovery of novel molecules against targets for CNS disorders, pain and inflammation January 10th 2018 - Milan (Italy) and Cambridge (UK) - Axxam S.p.A. and Proximagen Ltd. today announced a strategic...

Rewind Therapeutics, founded by Axxam and CD3, focusing on myelin-related diseases, raises €15.2 million in Series A Financing Round

Rewind Therapeutics, founded by Axxam and CD3, focusing on myelin-related diseases, raises €15.2 million in Series A Financing Round January 4th, 2018 - Milan (Italy) - Axxam is proud to announce that Rewind Therapeutics, a Belgian biotech company recently founded by...

leadXpro and Axxam enter collaboration on a GPCR lead discovery project

leadXpro and Axxam enter collaboration on a GPCR lead discovery project Milan, Italy, & Villigen, Switzerland, 1st of November 2017 - Axxam SpA and leadXpro AG announce today a collaboration for the discovery of novel small molecule lead compounds for a newly...

Axxam consolidates its collaboration with Genedata

Axxam consolidates its collaboration with Genedata September 27, 2017 - Axxam is glad to announce that the fruitful collaboration with Genedata, a leading provider of advanced software solutions for R&D, has been strengthened by the extension of the license for...

Subscribe to Our Newsletter 

Follow us on